Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy

Minerva Gastroenterologica e Dietologica

Volumn 48, Issue 3, 2002, Pages 215-226

  Fiocchi, C ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NONE   (United States)

Author keywords

Colitis, ulcerative; Crohn disease; Immunity, mucosal; Inflammatory bowel diseases, immunology; Inflammatory bowel diseases, therapy

Indexed keywords

AMINOSALICYLIC ACID; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYTOKINE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; CROHN DISEASE; DISEASE ASSOCIATION; ENTERITIS; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; MEASLES VIRUS; MOUSE; MYCOBACTERIUM PARATUBERCULOSIS; NONHUMAN; PATHOGENESIS; PEPTIC ULCER; REVIEW; RISK FACTOR; SALMONELLA; SHIGELLA; ULCERATIVE COLITIS;

EID: 0036764375     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Ermann J, Fatham CG. Autoimmune diseases: Genes, bugs and failed regulation. Nature Immunol 2001;2:759-61.
2. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998;115:182-205.
3. Cohen MB, Seidman E, Winter H, Colletti RB, Kirschner B, Balistrieri WF et al. Controversies in pediatric inflammatory bowel disease. Inflamm Bowel Dis 1998;4:203-27.
4. Cohen ML. Changing patterns of infectious disease. Nature 2000;406:762-7.
5. Barton JR, Gillon S, Ferguson A. Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, threefold increase in Crohn's disease. Gut 1989;30:618-22.
6. Olafsdottir EJ, Fluge G, Haug K. Chronic inflammatory bowel disease in children in western Norway. J Pediat Gastroenterol Nutr 1989;8:454-8.
7. Yoshida Y, Murata Y. Inflammatory bowel disease in Japan: Studies of epidemiology and etiopathogenesis. Med Clin North Am 1990;74:67-90.
8. Rhodes J, Thomas GAO. Smoking: Good or bad for inflammatory bowel disease? Gastroenterology 1994;106:807-10.
9. Hollander D, Vadheim C, Brettholz E, Pettersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives. Ann Intern Med 1986;105:883-5.
10. Peeters M, Geypens B, Ghoos Y, Nevens H, D'Haens G, Hiele H et al. Increased small intestinal permeability: A feature associated with Crohn's disease but not ulcerative colitis. Gastroenterology 1995;108:A892.
11. Farmer RG, Michener WM. Association of inflammatory bowel disease in families. Front Gastrointest Res 1986;11:17-26.
12. Cho JH, Brant SR. Genetics and genetic markers in inflammatory bowel disease. Curr Opin Gastroenterol 1998;14:283-8.
13. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al. A frameshift mutation in Nod2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
14. Hugot J-P, Chamaiilard M, Zouali H, Lesage S, Cezard J-P, Belaiche J et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
15. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1-Apaf-1 family member that is restricted to monocytes and activates NF-κB. J Biol Chem 2001;276:4812-8.
16. Wandstrat A, Wakeland E. The genetics of complex autoimmune diseases: Non-MHC susceptibility genes. Nature Immunol 2001;2:802-8.
17. Bargen JA. Experimental studies on the etiology of chronic ulcerative colitis. JAMA 1924;83:332-6.
18. Fidler HM, Thurrell W, Johnson NM, Rook GA, McFadden JJ. Specific detection of Mycobacterium paratuberculosis DNA associated with granulomatous tissue in Crohn's disease. Gut 1994;35:506-10.
19. VanKruiningen HJ. Lack of support for a common etiology in Johne's disease of animals and Crohn's disease in humans. Inflamm Bowel Dis 1999;5:183-91.
20. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobacterial therapy in Crohn's disease: Results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994;89:513-8.
21. Wakefield AJ, Sankey EA, Dhillon AP, Sawyerr AM, More L, Sim R et al. Granulomatous vasculitis in Crohn's disease. Gastroenterology 1991;100:1279-87.
22. Wakefield AJ, Pittilo RM, Sim R, Cosby SL, Stephenson JR, Dhillon AP et al. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol 1993;39:345-53.
23. Ekbom A, Wakefield AJ, Zack M, Adami HO. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994;344:508-10.
24. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ. Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 1995;345:1071-4.
25. D'Haens G, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions caused by infusion of intestinal contents in excluded ileum of Crohn's disease. Gastroenterology 1998;114:262-7.
26. Ruseler-van-Embden JGH, Schouten WR, van Lieshout LMC. Pouchitis: Result of microbial imbalance? Gut 1994;35:658-64.
27. Prantera C, Scribano ML, Berto E, Zannoni F. Antibiotic use in Crohn's disease. Why and how? Biodrugs 1997;8:293-306.
28. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
29. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, MeyerzumBuschenfelde K-H. Tolerance exists towards resident intestinal flora but it is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-55.
30. Duchmann R, Schmitt E, Knolle P, Buschenfelde KHMz, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interlukin-10 or antibodies to interleukin-12. Eur J Immunol 1996;26:934-8.
31. Zimmer C. Do chronic diseases have an infectious root? Science 2001;293:1974-7.
32. Fiocchi C. The immune system in inflammatory bowel disease. Acta Gastroenterol Belg 1997;60:156-62.
33. Scott MG, Nahm MH, Macke K, Nash GS, Bertovich MJ, MacDermott RP. Spontaneous secretion of IgG subclasses by intestinal mononuclear cells: Differences between ulcerative colitis, Crohn's disease, and controls. Clin Exp Immunol 1986;66:209-15.
34. MacDermott RP, Nash GS, Bertovich MJ, Mohrman RF, Kodner IJ, Delacroix DL et al. Altered patterns of secretion of monomeric IgA and IgA subclass 1 by intestinal mononuclear cells in inflammatory bowel disease. Gastroenterology 1986;91:379-85.
35. Takahashi F, Das KM. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis. J Clin Invest 1985;76:311-8.
36. Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990;98:464-9.
37. Shanahan F, Duerr RH, Rotter JI, Yang H, Sutherland LR, McElree C et al. Neutrophil autoantibodies in ulcerative colitis: Familial aggregation and genetic heterogeneity. Gastroenterology 1992;103:456-61.
38. McKenzie H, Main J, Pennington CR, Parratt D. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer' yeast) and Candida albicans in Crohn's disease. Gut 1990;31:536-8.
39. Present DH, Banks PA. The role of pANCA and ASCA in differentiating ulcerative colitis, Crohn's disease, and indeterminate colitis. Inflamm Bowel Dis 1999;5:66-7.
40. Kugathasan S, Willis J, Dahms BB, O'Riordan MA, Hupertz V, Binion DG et al. Intrinsic hyperreactivity of mucosal T-cells to interleukin-2 in pediatric Crohn's disease. J Pediatr 1998;133:675-81.
41. Ina K, Itoh J, Fukushima K, Kusugami K, Yamaguchi T, Kyokane K et al. Resistance of Crohn's disease T-cells to multiple apoptotic stimuli is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999;163:1081-90.
42. Itoh J, de la Motte C, Strong SA, Levine AD, Fiocchi C. Decreased Bax expression by mucosal T-cells favours resistance to apoptosis in Crohn's disease (CD). Gut 2001;49:35-41.
43. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
44. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nature Immunol 2001;2:816-22.
45. Weiner HL. The mucosal milieu creates toleragenic dendritic cells and TR1 and TH3 regulatory cells. Nature Immunol 2001;2:671-2.
46. Fiocchi C. Cytokines in Inflammatory Bowel Disease. Austin: R. G. Landes Company; 1996.
47. Targan SR, Hanauer SB, vanDeventer SJH, Mayer L, Present DH, Braakman T et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997;337:1029-35.
48. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA et al. Disparate CD4+ lamina propria lymphokine secretion profiles in inflammatory bowel disease. J Immunol 1996;157:1261-70.
49. Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997;112:1169-78.
50. Autschbach F, Braunstein J, Helmke B, Zuna I, Schurmann G, Niemir ZI et al. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol 1998;153:121-30.
51. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factor α and β in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996;110:975-84.
52. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001;108:601-9.
53. Fiocchi C. TGF-β/Smad signaling defects in inflammatory bowel disease: Mechanisms and possible novel therapies for chronic inflammation. J Clin Invest 2001;108:523-6.
54. Collins SM. Stress and the gastrointestinal tract IV. Modulation of intestinal inflammation by stress: Basic mechanisms and clinical relevance. Am J Physiol 2001;280:G315-8.
55. Panes J, Granger DN. Leukocyte-endothelial interactions: Molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998;114:1066-90.
56. Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110.
57. Fiocchi C. Intestinal inflammation: A complex interplay of immune-non immune cell interactions. Am J Physiol 1997;273:G769-75.
58. Mayer L, Eisenhardt D. Lack of induction of suppressor T-cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest 1990;86:1255-60.
59. Laroux FS, Grisham MB. Immunological basis of inflammatory bowel disease: Role of the microcirculation. Microcirculation 2001;8:283-301.
60. Binion DG, West GA, Ina K, Ziats NP, Emancipator SN, Fiocchi C. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 1997;112:1895-907.
61. Ina K, Kusugami K, Fiocchi C. Enhanced interaction of intestinal fibroblasts with T-cells in inflammatory bowel disease (IBD). Gastroenterology 1996;110:A930.
62. Musso A, Ina K, Fiocchi C. Extracellular matrix (ECM) from inflammatory bowel disease (IBD) displays enhanced adhesiveness for T-cells [abstract]. Gastroenterology 1996;110:977.
63. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 1999;11:648-56.
64. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL et al. The germ-free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994;180:2359-64.
65. Sands BE. Biologic therapy for inflammatory bowel disease. Inflamm Bowel Dis 1997;3:95-113.
66. Bickston SJ, Cominelli F. Recombinant interleukin 10 for the treatment of active Crohn's disease: Lessons in biologic therapy. Gastroenterology 2000;119:1781-3.
67. Yacyshyn B, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114:1133-42.
68. Schreiber S, Nicolaus S, Malchow H, Kruis W, Lochs H, Raedler A et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120:1339-46.
69. Lugering A, Schmidt M, Lugering N, Pauels H-G, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57.
70. ten Hoven T, van Montfrans C, Peppelenbosch MP, van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T-lymphocytes in Crohn's disease. Gut 2002;50:206-11.
71. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2002;345:1098-104.
72. Fuller R. A review: Probiotics in man and animals. J Appl Bacteriol 1989;66:365-78.
73. Shanahan F. Probiotics and inflammatory bowel disease: Is there a scientific rationale? Inflamm Bowel Dis 2000;6:107-15.
74. Gionchetti P, Campieri M. Probiotics and antibiotics in inflammatory bowel disease. Curr Opin Gastroenterol 2001;17:331-5.
75. Spencer DM, Veldman GM, Banerjee S, Willis J, Levine AD. Distinct inflammatory mechanisms mediate early and late colitis in IL-10 deficient mice. Gastroenterology 2002;122:94-105.
76. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heineken JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94.